Piramal Pharma Solutions Holds Grand Opening of its New Solid Oral Dosage Drug Product Facility in Sellersville, Pennsylvania

Sellersville, PA, September 21, 2020: Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), held a grand opening event at their recently acquired solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania.

 

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, addressed the guests remotely and explained that this acquisition broadens the offering of Piramal Pharma Solutions by adding solid oral dosage form capabilities (tablets and capsules) in North America. He stated, “This is a big day for us. We are rapidly growing and we take pride in the fact that we let our customer’s guide how and where we grow. The Sellersville facility is a great example of this. It was acquired because it addresses a market need for solid oral dosage form development and manufacturing in the United States. It also gives us new capabilities in liquids, creams, and ointments. As a leading CDMO offering end-to-end solutions across the drug life cycle, it’s vital that we provide our customers with a complete suite of services in all major geographies.”

 

Robert Harvie, Vice Chair of Bucks County Commissioners, spoke to the audience and welcomed PPS to the area. “Founded more than 350 years ago, this county has attracted people and businesses from all over the world because of its location and resources. We’re proud to still be attracting businesses like Piramal Pharma Solutions, which provides employment and economic benefits to our residents and produces valuable medicines that can quickly get to the people who need them.” Thomas Hufnagle, Mayor of Sellersville Borough, said, “It did my heart good to come here this morning and see the full parking lot at this site. It’s clear that this company is looking to building for the future, which makes this a great day.”

 

John Fowler, Chief Operating Officer, Piramal Pharma Solutions, also addressed the audience. Mr. Fowler stated, “Bringing the Sellersville site into the family significantly helps us accomplish our goal of getting medicines to patients. This is the thirteenth facility in our global network and our first solid dose facility in North America, giving us critical mass that matches local market need.” Stuart Needleman, Chief Commercial Officer, Piramal Pharma Solutions, added, “As a patient-centric organization, our mission is to help our customers reduce the burden of disease on patients. It’s the reason why we get up in the morning. And the Sellersville site most definitely enhances our ability to do that.”

***

 

Photo Caption: Piramal Pharma Solutions’ Sellersville Grand Opening. From left to right: Ken Yamashita, PPS; Jim Miller, West Rockhill Township Board of Supervisors; John Fowler, PPS; Thomas Hufnagle, Sellersville Borough Mayor; Robert Harvie, Vice Chair, Bucks County Commissioners; Stuart Needleman, PPS.

***

About Piramal Pharma Solutions:

Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide. For more information and updates, please visit: www.piramalpharmasolutions.com | Social Media: Twitter, LinkedIn

 

 

About Piramal Enterprises Limited:

Piramal Enterprises Limited (PEL) is one of India’s large diversified companies, with presence in Financial Services and Pharmaceuticals. PEL’s consolidated revenues were ~US$1.7 billion in FY2020, with ~34% of revenues generated from outside India.

Piramal Pharma Solutions is a part of PEL’s Pharma business that provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.) and sells a portfolio of niche differentiated pharma products leveraging its end-to-end manufacturing capabilities across 14 global facilities and a large global distribution network to over 100 countries. PEL is also active in the Consumer Products segment in India.

PEL also has a strong presence in Indian financial services sector. PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India. For more information and updates, please visit: www.piramal.com | Social Media: Facebook, Twitter, LinkedIn

 

For queries, please reach out to:

 

Investor Relations	Media
Hitesh Dhaddha | Sarang Nakadi investor.relations@piramal.com	Dimple Kapur | Riddhi Goradia | Amrita Verma dimple.kapur@piramal.com riddhi.goradia@piramal.com amrita.verma@piramal.com